CERUS CORP CERS 65.51
Health Care · NASDAQ · Data as of 2026-07-30
CERUS CORP (CERS) has delivered +23.0% annualized revenue growth, n/a earnings growth, and n/a dividend growth over 10 years of data. Ranked #383 of 1968 stocks overall and #36 of 260 in the Health Care sector by Steady Score.
About CERUS CORP
Company Overview
Cerus develops and sells the INTERCEPT Blood System, which reduces pathogens in donated blood components before transfusion. Blood centers use its equipment and disposable kits to treat platelets and plasma, and U.S. customers can produce INTERCEPT Fibrinogen Complex for bleeding associated with low fibrinogen. The company is also developing pathogen- reduction technology for red blood cells worldwide.
Read more
Business Model & Revenue
Product revenue comes mainly from disposable processing sets used each time blood is treated, supported by installed illuminators and service. Government contracts fund part of research and development. Blood collection volumes, regulatory approvals, reimbursement and adoption by blood centers drive sales. Manufacturing capacity, kit supply and clinical evidence are important, while research spending continues for additional components and markets.
Key Facts & Market Position
INTERCEPT addresses blood safety by treating components proactively rather than testing only for known pathogens. Regulatory status differs by component and country, so expansion requires clinical and agency review. A consumable model can generate repeat demand after adoption, but the company remains concentrated on one technology platform and specialized blood-center customers.